star-0215
mAbexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Jul 27, 2022 (NCT05477160)
Timeline
Indications
Mechanism of action
- Kallikrein 1INHIBITOR
Kallikrein 1 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068148 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07204938 | Phase 3 | Oct 1, 2025 | Astria Therapeutics, Inc. |
| NCT06842823 | Phase 3 | Mar 31, 2025 | Astria Therapeutics, Inc. |
| NCT06007677 | Phase 2 | Sep 26, 2023 | Astria Therapeutics, Inc. |
| NCT05695248 | Phase 1/Phase 2 (Phase 2) | Feb 21, 2023 | Astria Therapeutics, Inc. |
| NCT05477160 | Phase 1 | Jul 27, 2022 | Astria Therapeutics, Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Astria Therapeutics, Inc. | For profit | 5 | 5 | 3 | 2022 |
1 organizations
Page 1 / 1